UNSPSC 51361503: Dichloralphenazone

This classification denotes a sedative and hypnotic with the molecular formula C11H12N2O.2C2H3Cl3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YYX637R279, chemically known as 1,2-dihydro-1,5-dimethyl-2-phenyl-3h-pyrazol-3-one, compound with 2,2,2-trichloroethane-1,1-diol (1:2) but generally known as dichloralphenazone, which bears US NIH Compound Identifier 10188. European Medicines Agency schedules Dichloralphenazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13563MIG.

UNSPSC 51361503 Dichloralphenazone (Commodity) covers pharmaceutical products, but recent state and local solicitations show that governments actually procure this code for naloxone systems, safe drug deactivation equipment, generic multi-source pharmaceuticals, and over-the-counter products through both individual county purchases and multistate cooperative purchasing agreements. The code captures acquisition of emergency medical supplies and pharmaceutical inventory that support public health and community health initiatives, reflecting a broader pharmaceutical-procurement framework than the specific chemical compound name suggests. Issuing bodies include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple state and local jurisdictions; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and individual counties like Seminole County, Florida represent the mix of direct procurement and cooperative vehicle activity under the code.

Recent activity spans Florida and Minnesota, with Texas also soliciting in this space through its Health and Human Services Commission. Seminole County, Florida issued an IFB (Solicitation Number IFB60459723LAS) posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (Solicitation Number S1070000015802) posted January 20, 2026, with a March 26, 2026 proposal deadline, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with awarded vendors providing products to authorized wholesalers effective July 1, 2026. Texas HHS issued a Request for Information (RFI No. HHS0017013) posted April 3, 2026, to solicit vendor capabilities regarding direct-to-manufacturer prescription programs, signaling exploration of alternative pharmaceutical acquisition strategies.